Article | August 7, 2019

Tips For Viral Vector Production

Source: Cytiva

Towards a scalable and cost-efficient process

The viral vector market is highly active, and the interest in production technologies is driven by recent approvals in cell and gene therapy. Here we share insights around the challenges in viral vector manufacturing. The focus is on helping readers to obtain a scalable and cost-efficient process suitable for GMP manufacturing environments.

Viral vector capacity crunch

Demand for viral vector production is high. The main driver is the large pipeline in different clinical stages and scales. In 2018 there were more than 1000 clinical trials for cell and gene therapies, many of which use viral vectors. Adenoviruses and retroviruses, including lentivirus, are frequently used. Adeno-associated virus has grown rapidly the last few years, mostly in the gene therapy area. Also, development of oncolytic virus therapies and vaccines are further driving demand.

Compared with use in cell therapy, high-dose systemic administration for gene therapy requires more virus bulk. This means higher demands on process efficiency and production scale. Contract manufacturers are struggling to keep up with the demand for viral vectors. There is an urgent need to increase capacity for viral vector production, preferably using platform technologies.


Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.

Subscribe to Bioprocess Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Bioprocess Online